Lyell Immunopharma, Inc.
LYEL
$8.69
-$0.89-9.29%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 65.00K | 61.00K | 63.00K | 54.00K | 68.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 65.00K | 61.00K | 63.00K | 54.00K | 68.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 65.00K | 61.00K | 63.00K | 54.00K | 68.00K |
| SG&A Expenses | 52.59M | 52.04M | 50.69M | 54.42M | 61.20M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -4.55M | -4.25M | -3.89M | -3.45M | -3.04M |
| Total Operating Expenses | 219.92M | 219.40M | 216.73M | 225.25M | 239.64M |
| Operating Income | -219.85M | -219.34M | -216.66M | -225.20M | -239.58M |
| Income Before Tax | -334.52M | -342.99M | -203.99M | -210.26M | -228.34M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -334.52 | -342.99 | -203.99 | -210.26 | -228.34 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -334.52M | -342.99M | -203.99M | -210.26M | -228.34M |
| EBIT | -219.85M | -219.34M | -216.66M | -225.20M | -239.58M |
| EBITDA | -201.80M | -199.70M | -197.00M | -205.11M | -219.33M |
| EPS Basic | -24.32 | -25.55 | -16.03 | -16.59 | -18.11 |
| Normalized Basic EPS | -9.01 | -9.27 | -9.36 | -9.72 | -10.59 |
| EPS Diluted | -24.32 | -25.55 | -16.03 | -16.59 | -18.11 |
| Normalized Diluted EPS | -9.01 | -9.27 | -9.36 | -9.72 | -10.59 |
| Average Basic Shares Outstanding | 54.34M | 52.30M | 50.94M | 50.69M | 50.43M |
| Average Diluted Shares Outstanding | 54.34M | 52.30M | 50.94M | 50.69M | 50.43M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |